Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric bypass procedure in Texas.
The system received FDA approval during the previous fall to initiate human trials, serving both laparoscopic procedures and open soft tissue surgeries, as well as hybrid surgery models. The debut of Ottava for human use was originally planned for late 2022 but was delayed due to the pandemic’s technical difficulties and operational disturbances.
The company revealed that successful completion of the current study will enable FDA de novo clearance for multiple general surgery procedures in the upper abdominal area, including gastric bypass and sleeve surgeries and small bowel resections, and hiatal hernia repairs.
The system received testing during the trial at Memorial Hermann-Texas Medical Center through a Roux-en-Y procedure, which developed a smaller stomach pouch and directed it to the small intestine.
Hani Abouhalka from J&J MedTech expressed pride in the program achieving this vital robotic surgery point as group surgery chairman in his statement. The advanced surgical technology portfolio from our company includes Ottava as its core product, which is designed to transform all surgical operations.
The JJ product description states that Ottava works within standard operating room spaces and includes robotic arms that attach to a movable table, which can be stored below the floor. Operational instruments throughout Ottava’s setup belong exclusively to Ethicon, J&J’s surgical instruments division.
The patient table integrates with robotic arms to dynamically reposition patients while the operation continues uninterrupted.
